PPCB Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Not a good buy right now. PPCB is in a clear bearish trend (SMA200 > SMA20 > SMA5) with price (0.211) sitting just above near-term support (S2 ~0.205) and well below the pivot (0.327). There are no Intellectia buy signals, no news/catalysts, and the latest quarter shows no revenue and continued sizable losses—so an impatient investor has poor odds of getting a quick, favorable move from this entry.
Trend/structure: Bearish (SMA_200 > SMA_20 > SMA_5), indicating sustained downside pressure. Momentum: RSI_6 ~37 is weak (near oversold but not a clear reversal signal). MACD histogram is positive (0.00966) but contracting, implying any bounce is losing steam rather than strengthening. Levels: Current price ~0.211 is below S1 (0.251) and far below the pivot (0.327), so overhead resistance is heavy. Immediate support is near S2 (0.205); a break below increases downside risk. Pre-market is down (-5.18%), reinforcing near-term weakness. Pattern-based odds: Similar-pattern projection points to mild downside over the next week (-1.99%) and modest upside over the next month (+4.47%), but the near-term bias remains weak.
MACD histogram remains above zero (still some residual bullish momentum, though fading).
Statistical pattern suggests potential for a modest 1-month rebound (+4.47%).
No strong hedge fund/insider selling trend detected (neutral activity).
Primary trend is bearish (moving averages stacked bearishly), and price is well below pivot/resistance.
Pre-market weakness (-5.18%) and regular-session decline (-2.16%) suggest sellers remain in control.
No news in the past week—no clear event-driven catalyst to reverse sentiment.
Price is hovering near key support (S2 ~0.205); a breakdown could accelerate losses.
2026/Q1: Revenue was 0 (no YoY growth), indicating no operating traction. Profitability: Net income was -4,837,738 (still deeply negative despite the YoY percentage change), and EPS fell to -0.39 (down -98.92% YoY). Overall, the quarter reflects continued losses without revenue growth—fundamentals do not support an immediate buy setup for an impatient timeframe.
No analyst rating/price target change data was provided, suggesting limited or no actionable Wall Street coverage signals in this dataset. Wall Street-style view (pros/cons): Pros—biopharma optionality if a future catalyst appears. Cons—no revenue, ongoing losses, and a clearly bearish technical setup; without a defined catalyst, risk/reward is unattractive for buying now. Politicians/influential figures: No recent congress trading data available (no evidence of notable political buying/selling in the last 90 days).
